⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31659421 | 0.85 | — | — | |
| SCHEMBL5006618 | 0.82 | — | — | |
| SCHEMBL2099456 | 0.80 | — | — | |
| SCHEMBL16877906 | 0.78 | HIF1A (0.33) | — | |
| SCHEMBL5004160 | 0.78 | — | — | |
| SCHEMBL451665 | 0.78 | HIF1A (0.33) | — | |
| SCHEMBL16878051 | 0.78 | HIF1A (0.33) | — | |
| SCHEMBL1796614 | 0.77 | — | — | |
| SCHEMBL21538620 | 0.77 | — | — | |
| SCHEMBL25594610 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235434-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2025-07-24 | — | — | US | claimed |
| EP-4508053-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2025-02-19 | — | — | EP | claimed |
| CN-118974060-A | Rifabutin analogs for treating diseases | 生物验证系统股份公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2023198597-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-10-19 | — | — | WO | claimed |
| EP-2528910-B1 | 5-Alkynyl pyrimidines ahd their use as kinase inhibitors. | BOEHRINGER INGELHEIM INT (DE) | 2015-03-18 | — | — | EP | claimed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | claimed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | claimed |
| US-8618111-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-12-31 | — | — | US | claimed |
| EP-2528910-A1 | 5-ALKYNYL PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2012-12-05 | — | — | EP | claimed |
| US-20120028958-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| US-7317032-B2 | Imidazolyl inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB CO. (US) | 2008-01-08 | — | — | US | claimed |
| EP-1467995-A4 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050070589-A1 | Pyrazolyl inhibitors of 15- lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | claimed |
| US-20050070588-A1 | Imidazolyl inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | claimed |
| US-20050065198-A1 | Inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-24 | — | — | US | claimed |
| EP-1467995-A2 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030229067-A1 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | claimed |
| WO-2003053361-A2 | PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-0566069-A1 | Tachykinin receptor antagonists, isoquinolones and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | claimed |
| EP-0068331-B1 | TETRAHYDROFURAN COMPOUNDS AND ANALOGS THEREOF | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1986-01-15 | — | — | EP | claimed |